Opinion|Videos|January 17, 2025

Integrating Emerging BTKi Therapies Into Current Treatment Guidelines

Panelists discuss how the clinical implications of emerging Bruton tyrosine kinase inhibitor (BTKi)trials in mantle cell lymphoma (MCL) are addressing unmet needs by providing novel therapeutic options, and explore how the integration of these therapies into current chronic lymphocytic leukemia (CLL) and MCL treatment guidelines could reshape management strategies, with consideration given to factors such as efficacy, safety, and patient access.

Video content above is prompted by the following:

  1. What are the clinical implications of these trials, and which unmet needs are being addressed or potentially fulfilled in the MCL landscape?
  2. In the context of the evolving treatment landscape, how do you envision the integration of emerging BTKi therapies impacting current treatment guidelines for CLL and MCL? What factors should be considered?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo